Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed Stage I or Stage II Non-Small Cell Lung Cancer * Surgically resected at least 4 weeks ago but not more than 6 months ago * Bronchoalveolar carcinomas allowed * Completion of any chemotherapy or radiation given in conjunction with Surgery (neoadjuvant or adjuvant) * No evidence of disease following initial therapy evidenced by a CXR, CT or PET scan within 6 weeks of enrollment * ECOG performance status of 0 to 2 * Adequate organ and marrow function defined as follows: * Hemoglobin ≥9.0 gm/dL * Bilirubin \< 2.5 x upper limit of normal * AST \<2.5 x upper limit of normal * ALT \<2.5 x upper limit of normal * Creatinine \<3 mg/dL * Women of childbearing potential must have a negative pregnancy test and be willing to use acceptable methods of contraception through week 16. Exclusion Criteria: * Cardiovascular disease defined as: * New York Heart Association Class III or IV (Section 19.2) congestive heart failure * hemodynamically significant valvular heart disease * myocardial infarction within the last six months * active angina pectoris * uncontrolled ventricular arrhythmias * stroke within one year * known cerebrovascular disease * History of HIV, infectious hepatitis, or chronic immunosuppressive disease * concurrent shorter courses of immunosuppressive medications during and for 16 weeks after study treatment * History of an allergic reactions to any colony stimulating factor (GCSF, GMCSF) * Female patients must not be pregnant or breastfeeding. * History of participation in any investigational drug study within 4 weeks preceding initiation of study treatment.